Clinical trial
Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment…
NCT00306787 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00306787 |
|---|---|
| Title | Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes |
| Official title | A Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Patient-initiated Famciclovir 1000 mg b.i.d. x 1 Day to Valacyclovir 500 mg b.i.d. x 3 Days in Immunocompetent Adults With Recurrent Genital Herpes |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Genital Herpes |
| Intervention type | Drug |
| Interventions | Famciclovir, Valacyclovir, Placebo matching famciclovir, Placebo matching valacyclovir |
| Enrollment | 1,179 |
| Start date | Mar 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Mar 24, 2006 |
| Last update posted | Jun 30, 2011 |
| Countries | Australia, Canada, Germany, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: